GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xylo Technologies Ltd (STU:2QM0) » Definitions » Gross Margin %

Xylo Technologies (STU:2QM0) Gross Margin % : 9.50% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Xylo Technologies Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Xylo Technologies's Gross Profit for the six months ended in Dec. 2023 was €3.34 Mil. Xylo Technologies's Revenue for the six months ended in Dec. 2023 was €35.16 Mil. Therefore, Xylo Technologies's Gross Margin % for the quarter that ended in Dec. 2023 was 9.50%.


The historical rank and industry rank for Xylo Technologies's Gross Margin % or its related term are showing as below:

STU:2QM0' s Gross Margin % Range Over the Past 10 Years
Min: -94.73   Med: 14.32   Max: 67.94
Current: 12.91


During the past 12 years, the highest Gross Margin % of Xylo Technologies was 67.94%. The lowest was -94.73%. And the median was 14.32%.

STU:2QM0's Gross Margin % is ranked worse than
91.36% of 799 companies
in the Medical Devices & Instruments industry
Industry Median: 53.29 vs STU:2QM0: 12.91

Xylo Technologies had a gross margin of 9.50% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Xylo Technologies was 0.00% per year.


Xylo Technologies Gross Margin % Historical Data

The historical data trend for Xylo Technologies's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xylo Technologies Gross Margin % Chart

Xylo Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -66.67 -94.72 47.45 15.73 12.91

Xylo Technologies Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.32 17.71 14.52 15.36 9.50

Competitive Comparison of Xylo Technologies's Gross Margin %

For the Medical Devices subindustry, Xylo Technologies's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xylo Technologies's Gross Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xylo Technologies's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Xylo Technologies's Gross Margin % falls into.



Xylo Technologies Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Xylo Technologies's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=10.9 / 84.111
=(Revenue - Cost of Goods Sold) / Revenue
=(84.111 - 73.253) / 84.111
=12.91 %

Xylo Technologies's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=3.3 / 35.157
=(Revenue - Cost of Goods Sold) / Revenue
=(35.157 - 31.818) / 35.157
=9.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Xylo Technologies  (STU:2QM0) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Xylo Technologies had a gross margin of 9.50% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Xylo Technologies Gross Margin % Related Terms

Thank you for viewing the detailed overview of Xylo Technologies's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Xylo Technologies (STU:2QM0) Business Description

Traded in Other Exchanges
Address
10 Hanechoshet Street, 4th Floor, Tel Aviv, ISR, 6971072
Medigus Ltd is an Israel-based medical device company. It is engaged in the development, manufacturing, and marketing of surgical endostaplers and direct vision systems for minimally invasive medical procedures. The key product of the company is the MUSE (Medigus Ultrasonic Surgical Endostapler) system is a single-use device for the incisionless treatment of GERD (gastroesophageal reflux disease), which is based on proprietary platform technology and know-how. The company also develops a range of micro video cameras under the micro ScoutCam portfolio of products. It operates in five segments: Medical, E-Commerce, Online, Electric Vehicles, and Corporate. The company's geographical segments include the United States, United Kingdom, Germany, Israel, China, and Others.

Xylo Technologies (STU:2QM0) Headlines

No Headlines